Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fasting Condition
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The objective of the study is to compare the bioavailability and characterise the
pharmacokinetic profile of Mycophenolate mofetil 250 mg capsules Panacea Biotech Ltd, India
and Cellcept® 250 mg capsules Mycophenolate mofetil capsule, Roche Labs Inc. New Jersey, USA
in normal, healthy, adult human subjects under fasting conditions, and to assess the
bioequivalence.